A series of N-aryl-5,6,7,8-tetra-hydrobenzo[4,5]thieno [2,3-d]pyrimidin-4-amines were synthesized in moderate to good yield by using a microwave-enhanced conditions. The selected compounds were evaluated for their cytotoxic effects (IC 50 values) on human pulmonary carcinoma (A549), murine BALB/c spontaneous colon adenocarcinoma (CT26) and human hepatocellular liver carcinoma (HepG2) cell lines in vitro. Amongst these compounds, one compound was found to have the better cytotoxic activity with reference to the standard Erlotinib hydrochloride (Tarceva TM ) against A549 (IC 50 = 16.06 ± 0.09 μM) and HepG2 (IC 50 = 15.01 ± 0.31 μM) cell lines. Especially, two compounds showed best cytotoxic effects against CT26 (IC 50 = 11.38 ± 0.44 μM) and HepG2 (IC 50 = 8.51 ± 0.52 μM) cell lines, respectively. The preliminary structure-activity relationships were disclosed and the thieno[2,3-d]pyrimidine skeleton could be exploited to potential antitumor agents in the future.
Introduction
In investigation, we found the presence of several marketed anticancer drugs such as gefitinib I (Iressa™), 1 vandetanib II (Caprelsa™), 2 lapatinib III (Tykerb™), 3 erlotinib IV (Tarceva™), 4 tandutinib V (MLN518) (phase II clinical trials) 5 and icotinib VI (Conmana™) 6 ( Figure 1 ), which have a quinazoline nucleus, the thieno [2,3-d] pyrimidine core can be considered a bioisostere of this quinazoline core. 7 In literatures, [8] [9] [10] thieno [2,3-d] pyrimidin-4-amine derivatives exhibit a broad range of biological and pharmacological activities associated with their heterocyclic scaffold and have been widely used in the medical field. Thieno [2,3-d] pyrimidin-4-amine displays a wide range of biological activity including anti-tumor, 11 anti-bacterial, 12 anti-leukemia, 13, 14 antiviral, 15 anti-inflammatory 16 and anti-diabetic properties. 17 As such, many antitumor agents based on thieno [2,3-d] pyrimidine have been reported by researchers. Yang et al. 18 synthesized two series of thieno [2,3-d] pyrimidine derivatives and evaluated for cytotoxic activity in human pulmonary carcinoma cell line (A549). Of these compounds, one showed the most cytotoxic effect on A549 cells with half maximal inhibitory concentration (IC 50 ) value of 4.87 μM (Figure 2 , compound VII). Gryshchenko et al. 19 reported the synthesis of N-phenylthieno [2,3-d] pyrimidin-4-amines, and evaluated for their ability to inhibit enzymatic activity of the fibroblast growth factor receptor 1 (FGFR1). In these compounds, compounds VIII and IX exhibited most effects, with IC 50 values of 0.18 and 0.16 μM, respectively. Abbas et al. 20 synthesized two series of new tetrahydrobenzo [4, 5] thieno [2,3-d] pyrimidines (2,3-disubstituted derivatives and 2,4-disubstituted ones) and evaluated for their cytotoxic activity. According to the results, compound X was found to have the highest cytotoxic activity against breast MCF-7 with IC 50 = 15.01 μM, and XI showed to be the most active one to inhibit human hepatocellular liver carcinoma cell line (HepG2) with IC 50 = 1.29 μM. Besides, compound XII 21 showed the best FLT3 (FMS-like receptor tyrosine kinase 3) cytotoxic activity, with IC 50 value of 0.065 μM.
Herein, we take into consideration that the compounds of thieno [2,3-d] pyrimidine skeleton express an important biological cytotoxic activity, and intend to synthesize a series of thieno [2,3-d] pyrimidine derivatives.
In this study, we are interested in the widely reported cytotoxic activity of thieno [2,3-d] pyrimidine derivatives via different synthetic methods. Four strategies used for the synthesis of various thieno [2,3-d] pyrimidine scaffolds have been reported in literatures ( Figure 3) . 11, 14, [22] [23] [24] [25] [26] [27] [28] [29] The first method involves the synthesis of thieno [2,3-d] pyrimidin-4(3H)-one (XVII) from compounds XIV, XV and XVI, then, compound XVII is converted to 4-chlorothieno [2,3-d] pyrimidine (XIX), and the target compound XX is obtained from XIX. The second route is that the compound XIII is directly converted to compound XVII, and the final compound XX can be obtained from XVII. The third protocol is the direct synthesis of 4-chlorothieno [2,3-d] pyrimidine (XIX) from compound XV. The fourth method is the synthesis of compound XVIII from XV, subsequently, compound XV is converted to compound XIX, therefore, the target compound XX can be synthesized by XV.
Microwave irradiation technology in organic synthesis is a powerful tool for drug synthesis as it can speed up the reactions under mild conditions allowing the rapid preparation of compounds. 30 As mentioned above, microwave irradiation technology has been successfully applied to the synthesis of N-arylthieno [2,3-d] 33 by microwave irradiation technology ( Figure 4) . Interestingly, a compound of similar structure ( Figure 4 , compound XXIV) 34 was evaluated to inhibit EGFR (epidermal growth factor receptor) kinase activity with the enzyme inhibition IC 50 = 2.6 μM. Herein, thieno [2,3-d] pyrimidine skeleton of compounds XXIII and XXIV were used as a template, and the structure was modified: (Figure 4a ) hexatomic ring was linked to thiophene ring instead of five membered ring (compound XXIII); (Figure 4b ) substituted aromatic group was linked to secondary amine and -CH 2 group was subtracted (compound XXIV). Subsequently, compounds 3a-x (Scheme 1) were obtained.
In this study, two questions would be solved: (i) a series of N-aryl- 5,6,7,8- tetra hydrobenzo [4, 5] thieno [2,3-d] pyrimidin-4-amines (3a-x) were obtained with the aid of microwave irradiation technology ( Figure 5 ); (ii) the cytotoxic activity of synthesized compounds were evaluated against A549, murine BALB/c spontaneous colon adenocarcinoma cell line (CT26), and HepG2.
Results and Discussion

Synthesis
The synthetic strategy used in this study is outlined in Scheme 1. 2-Amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carbonitrile was prepared using a modified Gewald procedure via the reaction of cyclohexanone, malononitrile and sulfur in the presence of potassium carbonate (K 2 CO 3 ), which serves as a heterogeneous solid basic catalyst, in ethanol. To show the merits of the present work, we compared the as-obtained results using K 2 CO 3 with those previously reported in the literature. [35] [36] [37] [38] [39] [40] It was found that our method can achieve the target product in 95% yield in 15 min of reaction. Compared to the results in the literature, [35] [36] [37] [38] [39] [40] our method has a shorter reaction time and high yield. So, under the assistance of the microwave irradiation, K 2 CO 3 can act as a cheap, highly efficient, and green catalyst used to prepare compound 1 in high yield over a short reaction time.
As for the synthesis of the intermediate compound 2 The synthesis of compounds 3a-x (Table 1) involved the acid-catalyzed Dimroth rearrangement between compound 2 and an appropriate aromatic amine under microwave irradiation. It was found that the reaction between m, p-substituted aromatic amines and compound 2 can easily occur in high yield with a short reaction time. However, the reaction between o-substituted aromatic amines and compound 2 only formed trace amounts of the desired compounds under the same reaction conditions. This new synthetic route involves only three steps making this procedure simple and efficient. Hence, this method is an efficient method for the synthesis of N-arylthieno- The structures of all compounds 1, 2 and 3a-x were confirmed by infrared (IR), 1 H nuclear magnetic resonance (NMR), 13 C NMR spectroscopy, and high-resolution mass spectrometry (HRMS). The IR spectrum of compound 1 shows bands at 3444 and 2193 cm -1 corresponding to the -NH and -C≡N groups, respectively. For compound 2, the IR spectrum shows bands at 2199, 1627 and 1106 cm -1 corresponding to the -C≡N, -C=N and -C-N groups, respectively. For the sake of the assignment of 1 13 , probably assigned to 2-position hydrogen on the pyrimidine ring (-CH) and the 4-position at pyrimidine ring (-NH), respectively. In order to solve this assignment problem, D-H exchange technology was applied. One drop of D 2 O was added into the NMR sample of the compound 3h and it was found that the peak at d 8.13 disappeared. Thus, the peak at d 8.13 was assigned to the hydrogen of -NH and the other peak at d 8.38 assigned to the -CH signal.
To further confirm the structures of these compounds and provide a basis for studies on the structure activity relationships of these compounds, the crystal structures of compounds 3a and 3c were determined using single crystal X-ray diffraction. The molecular structures of the two compounds are illustrated in Figure 
Biological activity
Taking Erlotinib as reference compound, the synthesized compounds 3a-x were evaluated for cytotoxic activities of A549, CT26 and HepG2 cell lines using 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay. The inhibition (at 25 μM) of all target compounds and cytotoxic activities (IC 50 , in μM) for selected compounds were summarized in Table 2 .
As showed in Table 2 , compounds 3b, 3d, 3k, 3l, 3q, 3w and 3x displayed cytotoxic activities against A549 with drug concentration of 25 μM. Among the seven compounds, compounds 3b, 3d, 3k and 3w showed lower cytotoxicity (at 25 μM) than Erlotinib (25.18 ± 0.28%), with inhibition of 9.21 ± 0.12, 15.88 ± 0.45, 1.87 ± 0.21 and 17.84 ± 0.74%, respectively. Compounds 3l and 3x displayed better cytotoxic activity (37.18 ± 0.26 and 55.84 ± 0.05%) compared with the positive drug Erlotinib. Surprisingly, the most outstanding compound is 3q, which displayed best cytotoxic activity against A549 with the inhibition of 85.83 ± 0.31%.
Besides, most of target compounds (3b, 3d, 3e, 3f, 3g, 3h, 3j, 3m, 3n, 3o, 3p, 3q, 3r, 3s, 3t, 3u, 3v, 3w and 3x) were shown to have cytotoxic activities (at 25 μM) against CT26. In these compounds, the selected six compounds (3e, 3g, 3o, 3p, 3q and 3u) demonstrated inapparent cytotoxic activities compared with the positive control Erlotinib Interestingly, all of synthesized compounds were shown to have cytotoxic activities (at 25 μM) against HepG2. In these compounds, 3m (8.45 ± 0.59%) and 3o (2.72 ± 0.35%) demonstrated the lowest cytotoxic activities. Whereas, ten compounds (3a, 3c,  3f, 3g, 3h, 3k, 3l, 3p, 3s and 3u) Erlotinib (29.83 ± 0.21%). Besides, compounds 3b, 3d, 3j and 3w (33.57 ± 0.23, 33.94 ± 0.11, 47.98 ± 0.06 and 32.94 ± 0.54%) showed better cytotoxic activities than the positive drug. The most promising compounds 3q, 3v and 3x exhibited the best cytotoxic effects against HepG2 cell line with inhibition of 61.53 ± 0.26, 63.64 ± 0.17 and 66.66 ± 0.03%, respectively.
According to the analysis of above activity data, five compounds (3b, 3d, 3q, 3w and 3x) exhibited cytotoxic activities against all selected tumor cell lines (A549, CT26 and HepG2). Especially, compound 3q depicted better cytotoxic effects against A549 and HepG2 cell lines. In addition, 3t and 3x displayed the best cytotoxic effects against CT26 and HepG2 cell lines, respectively.
Three (3l, 3q and 3x), seven (3d, 3j, 3r, 3t, 3v, 3w  and 3x) and seven compounds (3d, 3j, 3q, 3r, 3v, 3w and   3x) , which have better cytotoxic activities compared to Erlotinib (at 25 μM), were subsequently severally selected to investigate the IC 50 values (Table 2 ) of cytotoxic activity against A549, CT26 and HepG2 cell lines, respectively.
The present study investigated the effect of several different structures and from the results of cytotoxic activities of the compounds, the following preliminary structure-activity relationships can be derived:
(i) The compound 3q showed the most outstanding cytotoxic activity (IC 50 = 16.06 ± 0.09 μM) and the next most promising compound was 3x, which displayed good cytotoxic activity (IC 50 = 21.38 ± 0.69 μM) against A549 cell line. Compound 3l showed moderate cytotoxic effects (IC 50 = 70.90 ± 0.22 μM). Based on this (Figure 7) , it is possible to surmise: when introducing a group with strong electron-donating (3q, Ar = p-t-BuPh) or strong electron-withdrawing (3x, Ar = p-CF 3 Ph) into the 4-position, the cytotoxic activity (A549) of compounds could be boosted. It was also observed that the presence of π-π conjugate effect (3l, Ar = m-AcPh) played an important role in the cytotoxic effect.
(ii) Subsequently, the introduction of strong electronwithdrawing group (3r, 3t and 3v, Ar = 3,4-DiClPh, 3,4-DiFPh and m-CF 3 Ph, respectively) led to a better cytotoxic activity (IC 50 = 22.91 ± 0.16, 19.05 ± 0.05, 22.39 ± 0.32 μM, respectively) against CT26 cell line (Figure 8) . Furthermore, the introduction of strong electron-donating (3w, Ar = m-t-BuPh) also improves the cytotoxic effect (IC 50 = 11.38 ± 0.44 μM) of the compound. Another interesting phenomenon was found that when introducing a double chlorine or a double fluorine (3r, Ar = 3,4-DiClPh; 3t, Ar = 3,4-DiFPh) into the 3,4-position, the resulting activity was higher than that of compounds 3s and 3u (Ar = 3,5-DiClPh; Ar = 3,5-DiFPh) with drug concentration of 25 μM. Besides, compounds 3d and 3j also displayed good cytotoxic activity (IC 50 = 45.71 ± 0.23 and 26.92 ± 0.18 μM, respectively) against CT26 cell line, which might be due to the presence of p-π conjugate effect (3j, Ar = m-MeOPh).
(iii) Meanwhile, compounds substituted with bulky electron-withdrawing (3x, Ar = p-CF 3 Ph; 3v, Ar = m-CF 3 Ph) or strong electron-donating groups (3q, Ar = p-t-BuPh) exhibited far superior cytotoxic activity (IC 50 = 8.51 ± 0.52, 14.02 ± 0.15 and 15.01 ± 0.31 μM, respectively) than other compounds ( Figure 9) . Moreover, the cytotoxic activity against HepG2 cell line was enhanced because of p-π conjugate effect (3d, Ar = m-ClPh; 3j, Ar = m-MeOPh), with IC 50 values of 29.81 ± 0.11 and 22.35 ± 0.36 μM, respectively.
(iv) To sum up, all of the synthesized compounds exhibited cytotoxic activities against HepG2 cell line with drug concentration of 25 μM, most of target compounds were shown to have cytotoxic activities against CT26 cell line, while only seven compounds demonstrated cytotoxic activities against A549 cell line. In general, it was found that all synthesized compounds showed significant selective cytotoxic effect against the HepG2.
The effects of selected compounds (IC 50 values of selected compounds > IC 50 values of Erlotinib against A549, CT26 and HepG2) on cell viability were assessed. The detailed results are provided in Figures 10, 11 and 12, respectively.
In relation to selectivity index (SI), Erlotinib showed SI > 1.92 and 2.32 for CT26 and HepG2 cells (Table 3 , entry 1), respectively. Compound 3v showed moderate SI = 2.75 for CT26 cell line (Table 3 , entry 4) and compounds 3t, 3w and 3v showed good selectivity index for CT26 cell line (Table 3, 
Conclusions
In conclusion, we have synthesized and evaluated a library of thieno[2,3-d]pyrimidine derivatives. Amongst these compounds (3a-x), 3q was found to have better cytotoxic activity with reference to the standard Erlotinib hydrochloride (Tarceva TM ) against A549 (IC 50 = 16.06 ± 0.09 μM) and HepG2 (IC 50 = 15.01 ± 0.31 μM) cell lines. Especially, 3w and 3x showed best cytotoxic effects against CT26 (IC 50 = 11.38 ± 0.44 μM) and HepG2 (IC 50 = 8.51 ± 0.52 μM) cell lines, respectively. Compound 3x also showed good selectivity index (SI > 11.75). Furthermore, additional preliminary structure-activity relationships could be responsible for the found potent and selective activity of new thieno[2,3-d]pyrimidine compounds. Besides, the synthesized compounds (3a-x) would be evaluated for their enzyme activities and protein activities in following work and the more complete structure-activity relationships would be disclosed.
Experimental
General remarks
All melting points were measured on an MP90 apparatus and are uncorrected. IR spectra were recorded in a VERTEX 80/Raman II (Bruker, Switzerland, KBr pellets). The 1 H NMR (400 MHz) and 13 C NMR (100 MHz) spectra were recorded in an Avance III HD (Bruker, Switzerland) spectrometer with tetramethylsilane (TMS) as internal reference in CDCl 3 or dimethyl sulfoxide (DMSO-d 6 ) as the solvent. Only discrete or characteristic signals for the 1 H NMR are reported. The MS spectra were obtained on a Triple-TOF™ 5600+ spectrometer (AB SCIEX, USA). An X-ray crystallographic analysis was performed with a Bruker SMART APEX II (Bruker, Switzerland). The structure of the single crystals was refined by a Shelx-97. 44 All reactions were monitored by thin layer chromatography (TLC) with ethyl acetate:hexane (1:4, v/v) as the eluent. All reagents and solvents had been purchased from commercial sources and commonly purified before their usage.
General procedure for preparation of 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carbonitrile (1) Cyclohexanone (0.98 g, 10 mmol), malononitrile (0.66 g, 10 mmol), sulfur powder (0.35 g, 11.0 mmol), K 2 CO 3 (0.28 g, 2.0 mmol) and 20 mL of dry ethanol were mixed and placed in a 50 mL pressure tube. The mixture was subjected to microwave irradiation (CEM Explorer Hybrid, USA, 100 W, 200 psi, 85 °C) for 15 min. After the reaction, the insoluble material was filtered out, and the solvent was removed through evaporation under reduced pressure. The crude product was washed with water and recrystallized from ethanol to give yellowish crystals of 1.69 g (9.50 mmol), in 95% yield; mp 146. 8 
Preparation of N'-(3-cyano-4,5,6,7-tetrahydrobenzo
Compound 1 (1.78 g, 10 mmol) and DMF-DMA (3.57 g, 30 mmol) were added into a 1-necked 20 mL pressure tube, and then the mixture was subjected to microwave irradiation (CEM Explorer Hybrid, USA, 100 W, 200 psi, 78 °C) for 5 min. After the reaction, the DMF-DMA was evaporated in vacuum and the crude compound was re-crystallized from ethyl acetate to give the target compound of 2.29 g (9.80 mmol), in 98% yield; mp 125. 8 -5,6,7,8-tetrahydrobenzo [4, 5] thieno [2,3- 
Preparation of N-aryl
d]pyrimidin-4-amines (3a-x)
Compound 2 (2.33 g, 10 mmol), appropriate aniline (11 mmol) and acetic acid (8 mL) as the solvent as well as catalyst were added into a 1-necked 20 mL pressure tube at room temperature. The mixture was subjected to microwave irradiation (CEM Explorer Hybrid, USA, 100 W, 200 psi, 90 °C) for 10 min. After reaction, the acetic acid was evaporated in a vacuum and the crude product was recrystallized from ethyl acetate to give target compounds (3a-x).
N-Phenyl- 5,6,7,8-tetrahydrobenzo [4, 5] thieno [2,3- -5,6,7,8-tetrahydrobenzo [4, 5] thieno [2,3- -5,6,7,8-tetrahydrobenzo [4, 5] thieno [2,3- (3, -5,6,7,8-tetrahydrobenzo [4, 5] thieno [2,3- 
Biological evaluation Cytotoxicity assay in vitro
At first, the cytotoxic activities of target compounds 3a-x were determined against A549, CT26 and HepG2 cell lines in vitro according to MTT assay with Erlotinib as the positive control at 25 μM. Then, the selected compounds, which have better cytotoxic effects compared to Erlotinib (at 25 μM), were subsequently severally selected to investigate the IC 50 values of cytotoxic activity against three tumor cell lines tested at six concentrations (3.125, 6.25, 12.5, 25, 50 and 100 μM). MTT was dissolved at 4 mg mL -1 in phosphatebuffered saline (PBS).
The three cancer cell lines were cultured in a Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 g mL -1 penicillin and 100 g mL -1 streptomycin. Cancer cell lines in logarithmic phase were plated at a density of 3 × 10 3 cells well -1 into each well of 96-well microtiter plates with 100 μL of DMEM and incubated at 37 °C for 24 h in humidified atmosphere containing 5% CO 2 . Then, compounds 3a-x solution (100 μL) was added into the culture medium and the cancer cells were incubated at same condition (37 °C, 5% CO 2 ) for 72 h. The MTT solution (20 μL of 4 mg mL -1 MTT in PBS) was added into each well and the cells containing target compounds were further incubated at 37 °C for 4 h in 5% CO 2 . After removing the culture medium, DMSO (200 μL) was then added into each well to dissolve the crystals, shaken mechanically for 10 min, and then optical densities (OD) values at a wavelength of 540 nm were measured on a microplate reader (SpectraMax 190, Molecular Devices, USA). Survival ratios are expressed in percentages with respect to untreated cells.
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